Breye Therapeutics ApS

CVR 40279865 · Private limited company (ApS) · Active · High risk

Breye Therapeutics ApS is a Private limited company (ApS), founded on , based in Hørsholm. The company is registered in the industry fremstilling af farmaceutiske præparater. Our model estimates a bankruptcy risk of 3.4% over the next 12 months, which is 2.4 times the average for Danish companies. 7 annual reports have been published, of which 1 more than six months after the end of the financial year. The latest annual report (31 Mar 2026) shows equity of DKK -126.2m and a net result of DKK -85.6m.

Bankruptcy risk for Breye Therapeutics ApS

3.4%
probability of bankruptcy within 12 months
High risk

2.4 × the average (1.41%) · higher risk than 88% of active Danish companies

Lowest riskHighest risk

Increases the risk

Equity ratio< -50% · bankruptcy rate 19.3%2.2×
Negative equityYes · bankruptcy rate 17.5%2.0×
Equity vs. share capital< 0× · bankruptcy rate 17.3%2.0×
Return on assets< -20% · bankruptcy rate 16.7%1.9×
Number of CEOs0 · bankruptcy rate 12.7%1.4×
CEOs in total (historical)0 · bankruptcy rate 12.4%1.4×
RegionHovedstaden · bankruptcy rate 11.6%1.3×
Annual reports filed late1 · bankruptcy rate 11.3%1.3×

Reduces the risk

Current ratio200%–500% · bankruptcy rate 3.4%0.39×
Share of late annual reports0.01%–25% · bankruptcy rate 4.5%0.51×
Number of auditors (historical)2 · bankruptcy rate 4.6%0.52×
Auditor registered in CVRYes · bankruptcy rate 4.8%0.55×
Audit opted outNo · bankruptcy rate 4.8%0.55×
Registered owners4+ · bankruptcy rate 5.7%0.65×
Reporting classReporting class B · bankruptcy rate 5.7%0.65×
Auditor's statementAudit · bankruptcy rate 5.8%0.66×

The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.

Company details

CVR number
40279865
Status
Active
Company type
Private limited company (ApS)
Founded
(7 years)
Address
Agern Alle 24
2970 Hørsholm
Municipality
Rudersdal
Industry
Fremstilling af farmaceutiske præparater (212000)
Bankruptcies in the industry: Fremstilling af farmaceutiske præparater
Share capital
DKK 1.0m
Auditor
EY Godkendt Revisionspartnerselskab
Audit opted out
No

Warning signs

Annual reports filed late1 of 7
Missing annual reportNo
Negative equityYes
Equity ratio-311.0%
Current ratio274%
Moves (last 2 years)0
CEO changes in total0
CEO's previous bankruptcies0
Other companies at the address74
Going-concern uncertaintyNo

Financials and key figures

Financial year202620252024
Gross profitDKK -7.7mDKK -7.5mDKK -7.8m
Net profitDKK -85.6mDKK -89.1mDKK -70.2m
EquityDKK -126.2mDKK -40.6mDKK 48.5m
Total assetsDKK 40.6mDKK 57.0mDKK 60.7m
CashDKK 29.2mDKK 43.1m–
Short-term debtDKK 13.0mDKK 95.7m–
Avg. employees33–

Latest annual report: Reporting class B · auditor's statement: Den uafhængige revisors erklæring · EY Godkendt Revisionspartnerselskab.

Filed annual reports

Reporting periodPublishedDays after period end
1 Apr 2025 – 31 Mar 2026185 Late
1 Apr 2024 – 31 Mar 2025176
1 Apr 2023 – 31 Mar 2024177
1 Apr 2022 – 31 Mar 2023182
1 Apr 2021 – 31 Mar 2022153
1 Apr 2020 – 31 Mar 2021167
13 Feb 2019 – 31 Mar 2020113

The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.

Management, owners and auditor

RoleNameFromTo
BoardJørgen Søberg PetersenCurrent
BoardUlrik MouritzenCurrent
BoardJimmy Arnold V Van HeusdenCurrent
BoardCarl Johan KördelCurrent
BoardGabriela BurianCurrent
BoardOskar Lukas Fredrik LjungströmCurrent
BoardRobert Glenn BlajezCurrent
BoardChiara Rossana Maria Liberati
Owner (33%)Novo Holdings A/SCurrent
Owner (15%)Sound Bioventures Fund I ABCurrent
Owner (5%)Sound Bioventures Fund I (D) ABCurrent
Owner (5%)Mission BioCapital VI LPCurrent
Owner (90%)Visus Holding ApS
Owner (5%)Bradford A. Young
Owner (33%)Novo Holdings A/S
Owner (33%)Visus Holding ApS
Owner (10%)BioInnovation Institute Fonden
Owner (5%)Sound Bioventures Fund I AB
Owner (10%)BII Holdings A/S
Owner (25%)Novo Holdings A/S
Owner (33%)Novo Holdings A/S
Owner (15%)Visus Holding ApS
Owner (5%)BII Holdings A/S
Owner (20%)Sound Bioventures Fund I AB
Owner (50%)Novo Holdings A/S
Owner (33%)Novo Holdings A/S
Owner (10%)Visus Holding ApS
Owner (5%)Golgi NueroSciences S.R.L.
AuditorEY Godkendt RevisionspartnerselskabCurrent
AuditorEMIT P/S
FounderVisus Holding ApSCurrent

Address history (1 moves)

Agern Alle 24, 2970 Hørsholm
Ved Hegnet 2, 2960 Rungsted Kyst

Former names

Breye Therapeutics ApS – now
Ciana Therapeutics ApS –
Visus Therapeutics ApS –

Other companies at the same address

Similar companies in Rudersdal

Questions and answers about Breye Therapeutics ApS

Has Breye Therapeutics ApS gone bankrupt?

No, Breye Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.

What is the bankruptcy risk of Breye Therapeutics ApS?

Our model estimates a bankruptcy risk of 3.4% over the next 12 months (high risk), which is 2.4 times the average for Danish companies.

Who is the auditor of Breye Therapeutics ApS?

Breye Therapeutics ApS most recently used EY Godkendt Revisionspartnerselskab.

When was Breye Therapeutics ApS founded?

Breye Therapeutics ApS was founded on 13 February 2019.

What is the equity of Breye Therapeutics ApS?

Equity was DKK -126.2m according to the annual report for the period ending 31 March 2026.

Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.